We are live on ! Find out more
HURA icon

TuHURA Biosciences

24 hedge funds and large institutions have $6.31M invested in TuHURA Biosciences in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

103% more capital inflows, than outflows

Capital inflows: $1.63M | Capital outflows: $807K

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

14% more funds holding

Funds holding: 21 → 24 (+3)

1.1% more ownership

Funds ownership: 7.43% → 8.53% (+1.1%)

Holders
24
Holders Change
+3
Holders Change %
+14.29%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
7
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

HURA Hedge Fund Activity: Q2 2021 in Review

24 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in TuHURA Biosciences (HURA) for Q2 2021, worth a combined $6.31M — up 60% from $3.95M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new HURA positions and 4 closed out — a net gain of 3 holders — while 7 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, adding an estimated $922K. The largest seller was Nantahala Capital Management, cutting an estimated $623K.

  • 24 institutional investors held TuHURA Biosciences (HURA) as of Q2 2021, up from 21 in Q1 2021.
  • Funds reported $6.31M of TuHURA Biosciences stock for Q2 2021, up 60% quarter-over-quarter.
  • 7 funds opened new TuHURA Biosciences positions in Q2 2021 and 4 closed out, a net change of +3 holders.
  • The largest TuHURA Biosciences buyer in Q2 2021 was Vanguard Group, an estimated $922K added.
  • The largest TuHURA Biosciences seller in Q2 2021 was Nantahala Capital Management, an estimated $623K sold.

Based on aggregated 13F filings for Q2 2021.